Polatuzumab vedotin-piiq (ADC)
Gecertificeerd

Polatuzumab vedotin-piiq (ADC)

Catalog #: DHE26399
Maat: 5 mg

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100

Technische Specificaties

Description

Polatuzumab vedotin (Polivy) is an ADC consisting of a CD79b-directed antibody and Monomethyl auristatin E (MMAE) that can be used in combination with bendamustine and rituximab for the treatment of adult patients with at least two relapses or refractory diffuse large B-cell lymphoma. Polatuzumab vedotin binds to CD79b and is internalized by tumor cells. MMAE is cleaved from cells by lysosomal protease and promotes tumor cell apoptosis by inhibiting microtubule formation.

Product Name Alternative

Polivy

Reactivity

Human

Applications

Research Grade Biosimilar

Stability

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks) . Store at -20°C 12 months. Store at -80°C long term.

Endotoxin

Please contact with the lab for this information.

Purity

>90% as determined by SEC.

Form

Liquid

Notes

For research use only. Not suitable for clinical or therapeutic use.

Beschrijving

Polatuzumab vedotin (Polivy) is an ADC consisting of a CD79b-directed antibody and Monomethyl auristatin E (MMAE) that can be used in combination with bendamust

Specificaties

ProductnaamPolatuzumab vedotin-piiq (ADC)
Categorie
Beschikbare grootte5 mg
CatalogusnummerDHE26399